Synthetic Genomics, Plenus Form New Company to Leverage Genomics for Agricultural Applications | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Synthetic Genomics and Plenus today announced the formation of a new firm, Agradis, to develop and commercialize products that leverage new technologies in genomics and plant breeding.

The companies also announced Agradis has raised $20 million in a Series A financing round to establish a corporate infrastructure and to support product development and commercialization.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.